Mark LaPre

Controller at Karuna Therapeutics, Inc.

Speaker

Mark is currently the Controller at Karuna Therapeutics, Inc., and joined the company in May 2019 prior to its IPO. Since then, the company has been through significant growth and multiple capital raises and has most recently been acquired by Bristol-Myers Squibb in March 2024, in conjunction with working towards commercialization for its lead product candidate, KarXT, for the treatment of acute psychosis in adults with schizophrenia. Mark’s prior experience includes approximately eleven years in public accounting at Deloitte and RSM.